Vivos Therapeutics, Inc. VVOS
Set alert
At close
Pre-market · Nov 2, 4:00 AM ET
- YTD
- -94.39%
- 1 year
- -95.59%
- Open
- 0.115
- Prev close
- 0.1206
- Mkt cap
- 3.82M
- Vol
- 709.43K
- Avg vol
- 15.04M
- EPS
- -1.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.111
- High
- 0.1191
- Forward P/E
- -9.31
- Beta
- 7.68
- Short ratio
- 0.66
- Inst. own
- 13.72%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 3.32
- 200-d avg
- 2.88
- 1y target
- 6.30
News
1 week ago benzinga.com
Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
3M shares rose 4.4% premarket after expanding its Amazon data-center deal, including a $521.4M stock warrant; other stocks saw sharp moves.
-
1 week ago benzinga.com
Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M
Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company") today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. ("SOD Sciences"
1 week ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
-
2 weeks ago benzinga.com
Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for